← feed

Is NCT03262610 results overdue?

Yes — results are overdue. Primary completion was 2018-01-31; the FDAAA-801 reporting deadline (2019-01-31) passed 2698 days ago and no results are posted on ClinicalTrials.gov.

Setmelanotide in a Single Patient With Partial Lipodystrophy

NCT IDNCT03262610 ↗
SponsorRhythm Pharmaceuticals, Inc. (INDUSTRY)
Public issuerRHYTHM PHARMACEUTICALS, INC. — RYTM (CIK 0001649904) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE2
StatusCOMPLETED
Primary completion2018-01-31 (ACTUAL)
Reporting deadline2019-01-31 (completion + 365d)
Days overdue2698
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 9b1f2abf844d9eb8… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03262610. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →